cd52

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS).

Tamtuvetmab (AT-005) is a caninised version of blontuvetmab targeting CD52. Tamtuvetmab (AT-005) enhances progression-free survival and demonstrates in vivo efficacy in naïve T-cell lymphoma (LSA) models in dogs and has received veterinary approval . Tamtuvetmab (AT-005) is utilized in veterinary oncology research focused on CD52-targeted immune cell depletion, T-cell lymphoma progression mechanisms, and antibody-mediated lymphoid cell modulation.

ANT1034 is an antibody targeting CD52 and can be used for oncology research.